1988
DOI: 10.1001/archopht.1988.01060140058024
|View full text |Cite
|
Sign up to set email alerts
|

Short-term Effects of Unilateral 1% Apraclonidine Therapy

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

7
26
1

Year Published

1988
1988
2011
2011

Publication Types

Select...
9
1

Relationship

0
10

Authors

Journals

citations
Cited by 96 publications
(34 citation statements)
references
References 14 publications
7
26
1
Order By: Relevance
“…These results are consistent with the known specificity of each ligand for adrenergic receptors [ 18], High density of receptors for U K -14,304 was found along the iris epithelium in the present experiments. These receptors would probably be located on the iris dilator muscles which run parallel to the iris epithelium, be cause alpha-2 adrenergic agonists are known to induce contraction of those muscles [1,2]. However, the present results cannot exclude a possibility that the iris epithelium itself has receptors for alpha-2 adrenergic agonists.…”
Section: Discussionmentioning
confidence: 43%
“…These results are consistent with the known specificity of each ligand for adrenergic receptors [ 18], High density of receptors for U K -14,304 was found along the iris epithelium in the present experiments. These receptors would probably be located on the iris dilator muscles which run parallel to the iris epithelium, be cause alpha-2 adrenergic agonists are known to induce contraction of those muscles [1,2]. However, the present results cannot exclude a possibility that the iris epithelium itself has receptors for alpha-2 adrenergic agonists.…”
Section: Discussionmentioning
confidence: 43%
“…The use of brimonidine in children is contraindicated due to its systemic side effect and its use in adults is limited by its ocular side effects such as allergy (Rahman et al, 2010). The relatively specific α2 adrenergic agonist, apraclonidine, is reported to reduce both AH formation and outflow resistance (Gharagozloo et al, 1988;Robin, 1988). 2.…”
Section: Medical Treatment Of Glaucomamentioning
confidence: 39%
“…This relatively se lective alpha-2-adrenergic agonist reduces intraocular pres sure (IOP) in normotensive volunteers and hypertensive pa tients [5][6][7][8]. In addition, it appears to reduce IOP further in patients treated with beta-blockers [9,10] as well as in pa tients taking maximally tolerated medications for various types o f glaucoma [11,12].…”
Section: Introductionsupporting
confidence: 46%